B6.129S2-Itgb3^tm1Hyn/JSemJ

Stock number: 008819
Product name: Β3-integrin KO
Research areas: Cardiovascular Research, Developmental Biology Research, Hematological Research, Internal/Organ Research

Description

These integrin beta 3 knock-out mutant mice exhibit significant embryonic lethality attributed to fetal hemorrhaging and placental defects. This mutant mouse strain represents a model that may be useful in studying Glanzmann thrombasthenia and other bleeding disorders.

Detailed description

Mice that are homozygous for this targeted allele have limited viability, with significant embryonic lethality attributed to fetal hemorrhaging and placental defects. Surviving mice are fertile. No gene product (protein) is detected on the surface of platelets. Pups surviving to three weeks of age may be subject to skin and gastrointestinal tract hemorrhaging. Gastrointestinal tract bleeding is commonly observed in adults and is frequently associated with an enlarged spleen. Erythrocyte number, hemoglobin, hematocrits and thrombus formation are all reduced while bleeding time is prolonged. Varying degrees of liver and kidney necrosis are also observed. Although increased numbers of osteoclasts are observed (3.5 fold over that seen in heterozygotes) they appear to be dysfunctional, having a reduced ability to resorb whale dentin in vitro. Mice are osteosclerotic and hypocalcemic. Enhanced tumor angiogenesis and vascular endothelial growth factor-induced blood vessel growth are observed. This mutant mouse strain represents a model that may be useful in studying Glanzmann thrombasthenia and other bleeding disorders.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development

This mutation was created by Dr. Richard O. Hynes (Massachusetts Institute of Technology) by designing a targeting vector to replace exons 1 and 2 of the targeted gene with a phosphoglycerate kinase promoter-driven neomycin resistance gene. The construct was transfected into 129S2/SvPas-derived D3 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts. The resulting chimeric animals were bred with C57BL/6 inbred mice, and maintained on a B6;129S2 genetic background prior to arrival at The Jackson Laboratory (as Stock No. 004669). Mice were obtained by Drs. Clay Semenkovich and Jochen G. Schneider (Washington University in St. Louis) and then bred to C57BL/6J inbred mice for at least 8-9 generations using a marker-assisted speed congenic approach prior to arrival at The Jackson Laboratory (as Stock No. 008819). Upon arrival, mice were bred with C57BL/6J for at least one generation to establish the colony.

Allele

Symbol: Itgb3^tm1Hyn
Name: targeted mutation 1, Richard Hynes
MGI accession ID: MGI:2175913
Generation method: Targeted
Attributes: Null/Knockout
Synonyms: Beta3; beta3 KO; beta3^-
Marker symbol: Itgb3
Marker name: integrin beta 3
Marker synonyms: BDPLT16; BDPLT2; BDPLT24; CD61; GP3A; GPIIIa; GT; GT2; platelet glycoprotein IIIa (GP3A)
Chromosome: 11
Strain of origin: 129S2/SvPas
Molecular note: A PGK-neomycin resistance cassette replaced 1.4 kb of sequence including exons I and II. FACS, immunoprecipitation, and immunofluorescence analyses did not detect protein expression in platelets and MEFs from homozygous mutant animals.